Dutton Associates Featured Company: NexMed, Inc. (NEXM)
NexMed, Inc. (NASDAQ: NEXM) engages in producing innovative medical treatments by utilizing their proprietary NexACT® drug delivery technology. The company works with large pharmaceutical companies offering their NexACT® drug delivery technology to be incorporated into existing drugs, allowing these companies to save enormously on research and development costs while developing new patient-friendly products which extend patent life-spans and brand equity. NexMed has partnerships with Novartis International Pharmaceutical Ltd. for licensing and marketing Onychomycosis treatment, an anti-fungal drug, and a licensing agreement with Warner Chilcott, Ltd. for exclusive rights to their topically applied treatment for erectile dysfunction (ED). NexACT is the…